Interstitial Lung Disease

About Interstitial Lung Disease

Interstitial lung disease is an umbrella term used to categorize over 100 different types of pulmonary disorders that affect the absorption of oxygen into the lungs. It includes a diverse collection of illnesses with a variety of causes, treatments and prognoses. Individuals who suffer from interstitial lung disease often have difficulty breathing and moving from place to place due to a consistent feeling of shortness of breath. Disorders classified under interstitial lung disease are often characterized by scarring of the lung’s delicate tissues, and a subsequent dry, pestering cough.

However,  interstitial lung disease may also develop without a known cause, and in that case it is known as idiopathic. The most common form of idiopathic interstitial lung disease is pulmonary fibrosis. As interstitial lung disease is a progressive disorder, identifying a known cause for the disease is especially important. Due to the fact that interstitial lung disease can be caused by environmental factors, removing these triggers may slow the progression of the disease and damage to the lungs. If the disease is idiopathic, cellular therapy for lung disease, and other forms of regenerative medicine have been found beneficial.

Symptoms of Interstitial Lung Disease

Sometimes symptoms will progress very quickly, and other times symptoms will remain mild to moderate for years until progressing rapidly in later stages. Sufferers may experience episodes in which their symptoms suddenly worsen; these episodes are referred to as acute flare-ups of the disease. Shortness of breath is the most common complaint of interstitial lung disease sufferers, other symptoms include:

Coughing
Weakness
Fatigue
Achy joints
Weight loss

Treating Interstitial Lung Disease

Smoking cessation is always the first step in treating a lung disease. Once you’ve visited with a pulmonologist you will likely get prescribed some medication to help your lung functioning, but note that interstitial lung disease does not have a known cure. It is also important that you regularly exercise your lungs and moderate your diet to help slow the progression of the disease. With all of these things, you may still not be satisfied with your ability to live a normal life.

The Lung Institute offers cellular therapy for interstitial lung disease. The cells used by the Lung Institute are autologous, which means they come from the patient’s own body. The cells are extracted from the patient’s own blood. Adult cells have the capacity to form many types of differentiated cells, so when the cells are returned to the patient, they will target the damaged tissue, which may lead to improved lung function in patients with a chronic lung disease. Our minimally invasive, outpatient procedures are changing lives by helping patients Breathe EasierTM.

Once the desired volume of cells are available, they are extracted from the patient’s blood. The cells are isolated and returned to the patient intravenously. Once the cells are returned to the patient, they may begin to slow down the progression of the disease. Since cells can continually replicate, the lungs can progressively grow stronger, and patients may see improved lung function.

If you would like to find out more about our available treatment options, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.

* Every patient is given a Patient Satisfaction Survey shortly after treatment. Responses to the 11-question survey are aggregated to determine patient satisfaction with the delivery of treatment.

^ Quality of Life Survey data measured the patient’s self-assessed quality of life and measurable quality of improvement at three months of COPD patients.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.

Each patient is different. Results may vary.